Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia

Clinical Neurophysiology

Volumn 115, Issue 2, 2004, Pages 396-401

  Becker, Jefferson ^a,b   Gomes, Irenio ^a,b   Ghisolfi, Eduardo S ^a,b   Schuch, Alice ^b   Paula Ramos, Fernanda L ^b   Ehlers, João Arthur ^a   Nora, Daniel B ^a,b   Lara, Diogo R ^a   Da Costa, Jaderson C ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Antipsychotics; Clozapine; Evoked potentials; P50; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVOKED RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PSYCHIATRIST; RATING SCALE; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

EID: 1642546270     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2003.09.018     Document Type: Article

References (36)

1. Adler L.E., Waldo M.C., Tatcher A., Cawthra E., Baker N., Freedman R. Lack of relationship of auditory gating defects to negative symptoms in schizophrenia. Schizophr Res. 3:(2):1990;131-138.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 150:(12):1993;1856-1861.
3. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull. 24:(2):1998;189-202.
4. Adler L.E., Cawthra E., Nagamoto H.T., Olincy A., McRae K.A., Waldo M.C., Freedman R. Confirmation of differing distribution of P50 ratios in schizophrenic patients versus controls. Biol Psychiatry. 47:2000;35S.
5. Arciniegas D.B., Topkoff J.L., Rojas D.C., Sheeder J., Teale P., Young D.A., Sandberg E., Reite M.L., Adler L.E. Reduced hippocampal volume in association with p50 non-suppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 13:(2):2001;213-221.
6. Boutros N.N. Dopamine and the P50. Biol Psychiatry. 44:(9):1998;936-937.
7. Boutros N., Zouridakis G., Rustin T., Peabody C., Warner D. The P50 component of the auditory evoked potential and subtypes of schizophrenia. Psychiatry Res. 47:(3):1993;243-254.
8. Boutros N.N., Gelernter J., Gooding D.C., Cubells J., Young A., Krystal J.H., Kosten T. Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data. Biol Psychiatry. 51:(8):2002;683-686.
9. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry. 41:(10):1997;1035-1044.
10. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry. 155:(12):1998;1691-1694.
11. Coon H., Byerley W., Holik J., Hoff M., Myles-Worsley M., Lannfelt L., Sokoloff P., Schwartz J.C., Waldo M., Freedman R. Linkage analysis of schizophrenia with 5 dopamine receptor genes in 9 pedigrees. Am J Hum Genet. 52:(2):1993;327-334.
12. Croft R.J., Lee A., Bertolot J., Gruzelier J.H. Associations of P50 suppression and desensitization with perceptual and cognitive features of 'unreality' in schizotypy. Biol Psychiatry. 50:(6):2001;441-446.
13. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 10:(2):1993;131-141.
14. Flach K.A., Adler L.E., Gerhardt G.A., Miller C., Bickford P., MacGregor R.J. Sensory gating in a computer model of the CA3 neural network of the hippocampus. Biol Psychiatry. 40:(12):1996;1230-1245.
15. Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmonte-de-Abreu P., Souza D.O., Lara D.R. The adenosine antagonist theophylline impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 27:(4):2002;629-637.
16. Griffith J.M., O'Neill J.E., Petty F., Garver D., Young D., Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry. 44:(2):1998;98-106.
17. Jin Y., Potkin S.G., Patterson J.V., Sandman C.A., Hetrick W.P., Bunney W.E. Jr. Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res. 70:(2):1997;71-81.
18. Jin Y., Bunney W.E. Jr, Sandman C.A., Patterson J.V., Fleming K., Moenter J.R., Kalali A.H., Hetrick W.P., Potkin S.G. Is P50 suppression a measure of sensory gating in schizophrenia? Biol Psychiatry. 43:(12):1998;873-878.
19. Judd L.L., McAdams L., Budnick B., Braff D.L. Sensory gating deficits in schizophrenia: new results. Am J Psychiatry. 149:(4):1992;488-493.
20. Kane J.M. Drug therapy: schizophrenia. N Engl J Med. 334:(1):1996;34-41.
21. Kane J.M., McGlashan T.H. Treatment of schizophrenia. Lancet. 346:1995;820-825.
22. Lara D.R., Souza D.O. Schizophrenia: a purinergic hypothesis. Med Hypotheses. 154:2000;157-166.
23. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry. 157:(5):2000;767-771.
24. Mitchell J.B., Lupica C.R., Dunwiddie T.V. Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. J Neurosci. 13:(8):1993;3439-3447.
25. Nagamoto H.T., Adler L.E., Waldo M.C., Griffith J., Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophr Res. 4:(1):1991;31-40.
26. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry. 40:(3):1996;181-188.
27. Nagamoto H.T., Adler L.E., McRae K.A., Huettl P., Cawthra E., Gerhardt G., Hea R., Griffith J. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4- hydroxyphenylglycol. Neuropsychobiology. 39:(1):1999;10-17.
28. Patterson J.V., Jin Y., Gierczak M., Hetrick W.P., Potkin S., Bunney W.E. Jr, Sandman C.A. Effects of temporal variability on p50 and the gating ratio in schizophrenia: a frequency domain adaptive filter single-trial analysis. Arch Gen Psychiatry. 57:(1):2000;57-64.
29. Ross R.G., Olincy A., Harris J.G., Radant A., Hawkins M., Adler L.E., Freedman R. Evidence for bilineal inheritance of physiological indicators of risk in childhood-onset schizophrenia. Am J Med Genet. 88:(2):1999;188-199.
30. Sadock B.J., Sadock V.A. Sadock B.J., Sadock V.A. Kaplan & Sadock's Comprehensive textbook of psychiatry. 2000;1096-1217 Lippincott Williams & Wilkins, Philadelphia.
31. Simosky J.K., Stevens K.E., Adler L.E., Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl). 165:(4):2003;386-396.
32. Waldo M., Gerhardt G., Baker N., Drebing C., Adler L., Freedman R. Auditory sensory gating and catecholamine metabolism in schizophrenic and normal subjects. Psychiatry Res. 44:(1):1992;21-32.
33. Waldo M., Myles-Worsley M., Madison A., Byerley W., Freedman R. Sensory gating deficits in parents of schizophrenics. Am J Med Genet. 60:(6):1995;506-511.
34. Ward P.B., Hoffer L.D., Liebert B.J., Catts S.V., O'Donnell M., Adler L.E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 64:(2):1996;121-135.
35. Yee C.M., Nuechterlein K.H., Morris S.E., White P.M. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol. 107:(4):1998;691-698.
36. Zouridakis G., Boutros N.N., Jansen B.H. A fuzzy clustering approach to study the auditory P50 component in schizophrenia. Psychiatry Res. 69:(2-3):1997;169-181.